Keloid and hypertrophic scars are challenging conditions frequently encountered in oral and maxillofacial surgery (OMFS). These scars result from excessive fibroblast proliferation and abnormal collagen deposition, often causing functional limitations and psychological distress. Triamcinolone acetonide, a synthetic corticosteroid, is widely recognized for its anti-inflammatory and antifibrotic properties, making it a valuable treatment option. This review examines the efficacy of triamcinolone in OMFS, its mechanisms of action, and its role in combination therapies. While monotherapy demonstrates significant improvements in scar reduction, integrating triamcinolone with surgical excision, laser therapy, and other adjunctive treatments enhances outcomes and minimizes recurrence. Findings underscore the importance of individualized treatment protocols and the need for further research into advanced therapeutic strategies.